This CME Activity has expired and is no longer available for credit.
Optimizing IBD Patient Care: "Advances in IBD" Conference Highlights
Time to Complete
November 7, 2012
November 7, 2013
1.25 / AMA PRA Category 1 Credit(s)TM 1.00 / CE for Nurses
Jointly sponsored by
Support for this activity has been provided through educational grants from Aptalis Pharma US, Inc.; Prometheus Pharmaceuticals; UCB; and Warner Chilcott.
This CME-certified activity is based on information presented at the 2011 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation of America's (CCFA) Clinical & Research Conference held December 1–3, 2011 in Hollywood, Florida.
Inflammatory bowel diseases (IBD) are chronic, inflammatory disorders that are characterized by alternating periods of active symptomatic disease and periods of remission. Because IBD is a lifelong condition, the importance of establishing and maintaining symptom control and remission is critical to minimizing complications. The treatment of active IBD has improved considerably, but a high rate of relapse is still associated with the disease, and maintaining remission can prove challenging to providers. Featuring highlights from the most widely attended presentations and seminars delivered by leading IBD experts from the CCFA’s 2011 “Advances in IBD” conference, this activity consists of a series of clinical discussions on the diagnosis and treatment of patients with IBD. CCFA is proud to present this activity as part of its commitment to furthering professional IBD education year-round. A written overview accompanies each recorded conversation to provide a more complete summary of the topic being discussed.
This activity has been designed to meet the educational needs of gastroenterologists, gastroenterology nurses, and other health care professionals with an interest in the treatment of pediatric and adult patients with IBD.
Upon completion of this activity, participants should be able to:
Describe recent developments regarding the diagnosis of IBD
Design strategies that incorporate the most recent evidence-based data to effectively treat adult IBD patients with conventional and biologic agents
Design effective monitoring and treatment strategies for pediatric and special populations with IBD that incorporate the most recent evidence-based data and expert consensus
Conflicts of Interest Disclosure Statements
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.
Miguel Regueiro, MD—Activity Co-Chair Professor of Medicine University of Pittsburgh School of Medicine Associate Chief, Education Clinical Head and Co-Director, Inflammatory Bowel Disease Center Pittsburgh, Pennsylvania
Miguel Regueiro, MD, has disclosed the following relevant financial relationships: Consultant: Abbott, Axcan, Janssen, Johnson and Johnson, Procter & Gamble, Prometheus Pharmaceuticals, Salix, Shire, UCB, Warner Chilcott
David T. Rubin, MD—Activity Co-Chair Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Associate Section Chief, Education Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine Chicago, Illinois
David T. Rubin, MD, has disclosed the following relevant financial relationships: Consultant: Abbott, Bristol-Myers Squibb, Centocor/Janssen, Elan, Exagen, Given Imaging, Ironwood, Lifecore Biomedical, Millennium/Takeda, Prometheus Pharmaceuticals, Salix, Shire, UCB Grant Support: Abbott, Elan, Salix, Shire, Prometheus Pharmaceuticals, Warner Chilcott Speaker: Merck
Marla C. Dubinsky, MD Associate Professor of Pediatrics Director, Pediatric Inflammatory Bowel Disease Center Cedars-Sinai Medical Center Los Angeles, California
Marla C. Dubinsky, MD, has disclosed the following relevant financial relationships: Consultant: Abbott, Janssen, Pfizer, Prometheus Labs Research Support: Janssen
Dr. Dubinsky discusses the unlabeled or investigational use of a commercial product.
Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine Chicago, Illinois
Stephen B. Hanauer, MD, has disclosed the following relevant financial relationships: Consultant/Clinical Research: Abbott, Janssen, Prometheus Labs, Millennium, UCB
James D. Lewis, MD, MSCE Professor of Medicine and Epidemiology Center for Clinical Epidemiology and Biostatistics Associate Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, Pennsylvania
James D. Lewis, MD, MSCE, has disclosed the following relevant financial relationships: Consultant: Abbott, Amgen, Millennium DSMD: Pfizer Investigator: Centocor Ortho Biotech, Shire, Takeda
Gil Melmed, MD, MS Clinical Assistant Professor of Medicine David Geffen School of Medicine Los Angeles, California
Gil Melmed, MD, MS, has disclosed the following relevant financial relationships: Consultant: Celgene, Janssen Investigator: Pfizer Speaker: Abbott, Prometheus Pharmaceuticals
Joel R. Rosh, MD, FAAP, FACG, AGAF Associate Professor of Pediatrics University of Medicine and Dentistry of New Jersey Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Morristown, New Jersey
Joel R. Rosh, MD, FAAP, FACG, AGAF, has disclosed the following relevant financial relationships: Consultant: Abbott, Janssen, Soligenix Investigator: Abbott, UCB Speakers Bureau: Abbott Nutrition
Dr. Rosh discusses the unlabeled or investigational use of a commercial product.
Corey A. Siegel, MD, MS Assistant Professor of Medicine The Dartmouth Institute for Health Policy and Clinical Practice Dartmouth Medical School Section of Gastroenterology and Hepatology Director, Inflammatory Bowel Disease Center Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire
Corey A. Siegel, MD, has disclosed the following relevant financial relationships: Consultant: Abbott, Elan, Janssen, Prometheus Pharmaceuticals, UCB Grant Support: Abbott, Janssen, Salix, UCB, Warner Chilcott Speaker: Abbott
Planning Committee Disclosures
Katherine Monday, CNP, has disclosed no relevant financial relationships.
Michelle Rubin, APN, CNS, CGRN, has disclosed no relevant financial relationships.
Curatio CME Institute Staff involved in the review of this activity have disclosed no financial relationships.
Penn State College of Medicine Faculty and staff involved in the review of this activity have disclosed no financial relationships.
The Crohn’s & Colitis Foundation of America Faculty and staff involved in the review of this activity have disclosed no financial relationships.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Penn State College of Medicine and the Crohn's & Colitis Foundation of America (CCFA). Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
This activity is co-sponsored by Curatio CME Institute, an ACCME-accredited provider.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
This continuing nursing education activity was approved by the Society of Gastroenterology Nurses and Associates, Inc., an accredited approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SGNA designates this activity for 1.00 contact hours.
Note: According to the criteria of the American Board of Certification for Gastroenterology Nurses (ABCGN), 1.00 hours earned in this activity is considered GI-specific for purposes of re-certification by contact hours through ABCGN. For re-certification you may need to retain this document up to 6 years.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Crohn’s & Colitis Foundation of America; Penn State College of Medicine; Curatio CME Institute; Aptalis Pharma US, Inc.; Prometheus Pharmaceuticals; UCB; and Warner Chilcott do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the Crohn’s & Colitis Foundation of America; Penn State College of Medicine; Curatio CME Institute; Aptalis Pharma US, Inc.; Prometheus Pharmaceuticals; UCB; or Warner Chilcott. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse regarding diagnosis and treatment of a specific patient’s medical condition.
Method of Participation There are no fees for participating in this CME activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 70% or better on the post-test. The post-test can be accessed at the end of the activity.
If you have any questions relating to the accreditation or your certificate for this activity, please contact Penn State at ContinuingEd@hmc.psu.edu or (717) 531-6483. Reference course #G5187-13-T.
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming CCFA and other programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.